# A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

> **NCT04162769** · PHASE2 · COMPLETED · sponsor: **Arena Pharmaceuticals** · enrollment: 140 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Etrasimod 1 mg
- **DRUG:** Etrasimod 2 mg
- **DRUG:** Etrasimod matching placebo

## Key facts

- **NCT ID:** NCT04162769
- **Lead sponsor:** Arena Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-04
- **Primary completion:** 2020-09-09
- **Final completion:** 2021-10-11
- **Target enrollment:** 140 (ACTUAL)
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162769, "A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04162769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*